Current Report Filing (8-k)
April 21 2021 - 3:32PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported)
April
20, 2021
ONCOTELIC
THERAPEUTICS, INC.
(Formerly
Mateon Therapeutics, Inc.)
(Exact
name of registrant as specified in its charter)
Delaware
|
|
000-21990
|
|
13-3679168
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
29397
Agoura Road Suite 107
Agoura
Hills, CA 91301
(Address
of principal executive offices and Zip Code)
Registrant’s
telephone number, including area code
(650)
635-7000
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of class
|
|
Trading
Symbols
|
|
Name
of each exchange on which registered
|
N/A
|
|
N/A
|
|
N/A
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
On
April 20, 2021, Oncotelic Therapeutics, Inc. (f/k/a Mateon Therapeutics, Inc.) (the “Company”) issued a press release
announcing positive top line data from its COVID-19 clinical trial, ARTI-19. A copy of the press release dated April 20, 2021 is furnished
as Exhibit 99.1 hereto and is incorporated herein by reference.
Item
9.01
|
Financial
Statements and Exhibits.
|
(d)
Exhibits.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
ONCOTELIC
THERAPEUTICS, INC.
|
|
|
|
Date:
April 21, 2021
|
By:
|
/s/
Vuong Trieu
|
|
|
Vuong
Trieu
|
|
|
Chief
Executive Officer
|
Oncotelic Therapeutics (QB) (USOTC:OTLC)
Historical Stock Chart
From Apr 2024 to May 2024
Oncotelic Therapeutics (QB) (USOTC:OTLC)
Historical Stock Chart
From May 2023 to May 2024